

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
23 November 2006 (23.11.2006)

PCT

(10) International Publication Number
WO 2006/123953 A1

(51) International Patent Classification:

C07D 473/00 (2006.01) C07D 473/04 (2006.01)
A61K 31/52 (2006.01) C07D 473/18 (2006.01)
A61K 31/522 (2006.01) C07D 473/30 (2006.01)
A61P 31/00 (2006.01) C07D 473/34 (2006.01)

Creswick Terrace, Northland, Wellington (NZ). MEE, Simon, Peter, Harold [NZ/NZ]; 29 Tennyson Street, Petone, Lower Hutt (NZ). ZUBKOVA, Olga, Vladimirovna [NZ/NZ]; 110a Allington Rd, Karori, Wellington (NZ).

(21) International Application Number:

PCT/NZ2006/000123

(74) Agent: BALDWINS; P O Box 852, Wellington (NZ).

(22) International Filing Date: 22 May 2006 (22.05.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
540160 20 May 2005 (20.05.2005) NZ

(71) Applicants (for all designated States except US): ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY [US/US]; 1300 Morris Park Avenue, Bronx, NY 10461 (US). INDUSTRIAL RESEARCH LIMITED [NZ/NZ]; Gracefield Research Centre, 69 Gracefield Road, Lower Hutt (NZ).

(72) Inventors; and

(75) Inventors/Applicants (for US only): EVANS, Gary, Brian [NZ/NZ]; 50 Pekanga Road, Normandale, Lower Hutt (NZ). FURNEAUX, Richard, Hubert [NZ/NZ]; 35 Huntington Street, Wilton, Wellington (NZ). SCHRAMM, Vern, L. [US/US]; 68 Hampton Oval, New Rochelle, NY 10805 (US). TYLER, Peter, Charles [NZ/NZ]; 143

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND NUCLEOSIDASES

(57) Abstract: The present invention relates to compounds of the general formula (I) which are inhibitors of purine nucleoside phosphorylases (PNP), purine phosphoribosyltransferases (PPRT), 5'-methylthioadenosine phosphorylases (MTAP), 5'-methylthioadenosine nucleosidases (MTAN) and/or nucleoside hydrolases (NH). The invention also relates to the use of these compounds in the treatment of diseases and infections including cancer, bacterial infections, protozoal infections, and T-cell mediated disease and to pharmaceutical compositions containing the compounds.

WO 2006/123953 A1

INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND NUCLEOSIDASES

TECHNICAL FIELD

This invention relates generally to certain nucleoside analogues, the use of these compounds as pharmaceuticals, pharmaceutical compositions containing the compounds, processes for preparing the compounds, and methods of treating diseases or conditions in which it is desirable to inhibit purine phosphoribosyltransferase, purine nucleoside phosphorylase, 5'-methylthioadenosine phosphorylase, 5'-methylthioadenosine nucleosidase and/or nucleoside hydrolase.

BACKGROUND

US 5,985,848, US 6,066,722 and US 6,228,741 describe nucleoside analogues that are inhibitors of purine nucleoside phosphorylase (PNP) and purine phosphoribosyltransferases (PPRT). The analogues are useful in treating parasitic infections, T-cell malignancies, autoimmune diseases and inflammatory disorders. The analogues are also useful for immunosuppression in organ transplantation.

PCT/NZ00/00048 describes a process for preparing certain PNP inhibitor compounds. This application recognises the compounds as PNP inhibitors and addresses a need for simpler methods of preparing them. PCT/NZ01/00174 discloses further nucleoside analogues that are inhibitors of PNP and PPRT.

Certain nucleoside analogues have also been identified as potent inhibitors of 5'-methylthioadenosine phosphorylase (MTAP) and 5'-methylthioadenosine nucleosidase (MTAN). These are the subject of PCT/NZ03/00050.

PNP catalyses the phosphorolytic cleavage of ribo- and deoxyribonucleosides, for example those of guanine and hypoxanthine, to give the corresponding sugar-1-phosphate and guanine, hypoxanthine or other purine bases.

Humans deficient in purine nucleoside phosphorylase (PNP) suffer a specific T-cell immunodeficiency due to an accumulation of dGTP which prevents proliferation of stimulated T lymphocytes. Inhibitors against PNP are therefore immunosuppressive, and are active against T-cell malignancies and T-cell proliferative disorders.

Nucleoside hydrolases (NH) catalyse the hydrolysis of nucleosides. These enzymes are not found in mammals but are required for nucleoside salvage in some protozoan parasites. Some protozoan parasites use nucleoside phosphorylases either instead of or in addition to nucleoside hydrolases for this purpose. Inhibitors of nucleoside hydrolases and phosphorylases can be expected to interfere with the metabolism of the parasite and can therefore be usefully employed against protozoan parasites.

MTAP and MTAN function in the polyamine biosynthesis pathway, in purine salvage in mammals, and in the quorum sensing pathways in bacteria. MTAP catalyses the reversible phosphorolysis of 5'-methylthioadenosine (MTA) to adenine and 5-methylthio- α -D-ribose-1-phosphate (MTR-1P). MTAN catalyses the reversible hydrolysis of MTA to adenine and 5-methylthio- α -D-ribose and of S-adenosyl-L-homocysteine (SAH) to adenine and S-ribosyl-homocysteine (SRH). The adenine formed is subsequently recycled and converted into nucleotides. Essentially, the only source of free adenine in the human cell is a result of the action of these enzymes. The MTR-1P is subsequently converted into methionine by successive enzymatic actions.

MTA is a by-product of the reaction involving the transfer of an aminopropyl group from decarboxylated S-adenosylmethionine to putrescine during the formation of spermidine. The reaction is catalyzed by spermidine synthase. The spermidine synthase is very sensitive to product inhibition by accumulation of MTA. Therefore, inhibition of MTAP or MTAN severely limits the polyamine biosynthesis and the salvage pathway for adenine in the cells. Likewise, MTA is the by-product of the bacterial synthesis of acylated homoserine lactones from S-adenosylmethionine (SAM) and acyl-acyl carrier proteins in which the subsequent lactonization causes release of MTA and the acylated homoserine lactone. The acylated homoserine lactone is a bacterial quorum sensing molecule in bacteria that is involved in bacterial virulence against human tissues. Recent work has identified a second communication system (autoinducer 2, AI-2) that is common to both Gram-positive and Gram-negative bacteria and thus has been proposed as a "universal signal" which functions in interspecies cell-to-cell communication. Again, MTAN generates S-ribosyl-homocysteine (SRH) that is the precursor of AI-2. Inhibition of MTAN or MTAP in microbes will prevent MTA removal and subject the pathway to product inhibition, thereby decreasing production of the quorum sensing pathway and decreasing the virulence of microbial infections. Inhibition of MTAN in microbes will prevent the formation of SRH, decreasing the production of the second quorum sensing pathway.

MTAP deficiency due to a genetic deletion has been reported with many malignancies. The loss of MTAP enzyme function in these cells is known to be due to homozygous deletions on chromosome 9 of the closely linked MTAP and *p16/MTS1* tumour suppressor gene. As absence of *p16/MTS1* is probably responsible for the tumour, the lack of MTAP activity is a consequence of the genetic deletion and is not causative for the cancer. However, the absence of MTAP alters the purine metabolism in these cells so that they are mainly dependent on the *de novo* pathway for their supply of purines. That makes these cells unusually sensitive to inhibitors like methotrexate, alanosine and azaserine, that block the *de novo* pathway. Therefore, a combination therapy of methotrexate, alanosine or azaserine with an MTAP inhibitor will have unusually effective anti-tumour properties.

MTAP inhibitors would also be very effective against parasitic infection such as malaria that infects red blood cells (RBCs), as they lack the *de novo* pathway for purine biosynthesis. Protozoan parasites depend entirely upon the purines produced by the salvage pathway for their growth and propagation. MTAP inhibitors will therefore kill these parasites without having any negative effect on the host RBCs, as RBCs are terminally differentiated cells and they do not synthesize purines, produce polyamines or multiply.

The imino sugar part of the compounds described in the patent specifications referred to above has the nitrogen atom located between C-1 and C-4 so as to form 1,4-dideoxy-1,4-imino-D-ribitol compounds. The location of the nitrogen atom in the ribitol ring may be critical for binding to enzymes. In addition, the location of the link between the sugar moiety and the nucleoside base analogue may be critical for enzyme inhibitory activity. The compounds described above have that link at C-1 of the sugar ring.

The applicants have also developed other nucleoside phosphorylase and nucleosidase inhibitors, where the location of the nitrogen atom in the sugar ring is varied and, additionally, where two nitrogen atoms form part of the sugar ring. Alternative modes of linking the sugar part and the base analogue have also been investigated, resulting in a class of inhibitors where the sugar moiety is linked to the nucleoside base analogue via a methylene bridge. These other inhibitors are described in PCT/NZ03/00186.

However, there remains an ongoing need for new inhibitors of PNP, PPRT, MTAP, MTAN, and NH. In particular, the applicants have now found that ethylene-linked analogues of

- 4 -


the abovementioned methylene-linked compounds are surprisingly potent inhibitors of PNP. The same class of compounds are anticipated to be inhibitors of PPRT, MTAP, MTAN, and NH.

5

It is therefore an object of the present invention to provide compounds that are inhibitors of PNP, PPRT, MTAP, MTAN, and/or NH, or to at least provide a useful choice.

STATEMENTS OF INVENTION

10 Accordingly, in a first aspect, the present invention provides a compound of the formula (I):



where:

- 15 A is N or CH;
 B is OH or NH₂;
 D is H, OH, NH₂ or SCH₃; and
 Z is OH or SQ, where Q is an optionally substituted alkyl, aralkyl, or aryl group;
 20 or a tautomer thereof, or a pharmaceutically acceptable salt thereof, or an ester prodrug form thereof.

Preferably A is CH. Alternatively, A may be N.

25 It is also preferred that B is OH. Alternatively, B is NH₂.

It is further preferred that D is H. Alternatively, D may preferably be NH₂, OH, or SCH₃.

30 In some preferred compounds of the invention Z is OH. In other preferred compounds Z is SQ.

Further preferred compounds of the invention are those where Z is OH, A is CH, B is OH, and D is H or NH₂.

- 5 Other preferred compounds of the invention are those where Z is SQ, A is CH, B is NH₂, and D is H.

Preferred compounds of the invention include:

- 10 (i) (3S,4S)-1-[(9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(hydroxymethyl)-pyrrolidine;
- (ii) (3S,4R)-1-[(9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(methylthiomethyl)-pyrrolidine;
- (iii) (3S,4R)-1-[(9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(ethylthiomethyl)-pyrrolidine;
- 15 (iv) (3S,4R)-1-[(9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(2-fluoroethylthiomethyl)-pyrrolidine;
- (v) (3S,4R)-1-[(9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(2-hydroxyethylthiomethyl)-pyrrolidine;
- 20 (vi) (3S,4R)-1-[(9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(propylthiomethyl)-pyrrolidine;
- (vii) (3S,4R)-1-[(9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(isopropylthiomethyl)-pyrrolidine;
- (viii) (3S,4R)-1-[(9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(butylthiomethyl)-pyrrolidine;
- 25 (ix) (3S,4R)-1-[(9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(cyclohexylthiomethyl)-pyrrolidine;
- (x) (3S,4R)-1-[(9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(cyclohexylmethylthiomethyl)-pyrrolidine;
- 30 (xi) (3S,4R)-1-[(9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(cyclopentylthiomethyl)-pyrrolidine;
- (xii) (3S,4R)-1-[(9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(phenylthiomethyl)-pyrrolidine;
- (xiii) (3S,4R)-1-[(9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(4-fluorophenylthiomethyl)-pyrrolidine;
- 35 (xiv) (3S,4R)-1-[(9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(4-chlorophenylthiomethyl)-pyrrolidine;

- (xv) (3S,4R)-1-[(9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(3-chlorophenylthiomethyl)-pyrrolidine;
- (xvi) (3S,4R)-1-[(9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(4-methylphenylthiomethyl)-pyrrolidine;
- 5 (xvii) (3S,4R)-1-[(9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(3-methylphenylthiomethyl)-pyrrolidine;
- (xviii) (3S,4R)-1-[(9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(benzylthiomethyl)-pyrrolidine;
- 10 (xix) (3S,4S)-1-[(9-deazaguanin-9-yl)ethyl]-3-hydroxy-4-(hydroxymethyl)-pyrrolidine;
- (xx) (3S,4R)-1-[(9-deazaguanin-9-yl)ethyl]-3-hydroxy-4-(methylthiomethyl)-pyrrolidine;
- (xxi) (3S,4S)-1-[(9-deazahypoxanthin-9-yl)ethyl]-3-hydroxy-4-(hydroxymethyl)-pyrrolidine;
- 15 (xxii) (3S,4R)-1-[(9-deazahypoxanthin-9-yl)ethyl]-3-hydroxy-4-(methylthiomethyl)-pyrrolidine;
- (xxiii) (3S,4S)-1-[(9-deazaxanthin-9-yl)ethyl]-3-hydroxy-4-(hydroxymethyl)-pyrrolidine;
- 20 (xxiv) (3S,4S)-1-[(9-deazaxanthin-9-yl)ethyl]-3-hydroxy-4-(methylthiomethyl)-pyrrolidine;
- (xxv) (3S,4S)-1-[(8-aza-9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(hydroxymethyl)-pyrrolidine;
- (xxvi) (3S,4S)-1-[(8-aza-9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-methyl-pyrrolidine;
- 25 (xxvii) (3S,4R)-1-[(8-aza-9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(benzylthiomethyl)-pyrrolidine;
- (xxviii) (3S,4R)-1-[(8-aza-9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(methylthiomethyl)-pyrrolidine;
- (xxix) (3S,4R)-1-[(8-aza-9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(ethylthiomethyl)-pyrrolidine;
- 30 (xxx) (3S,4R)-1-[(8-aza-9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(propylthiomethyl)-pyrrolidine;
- (xxxi) (3S,4R)-1-[(8-aza-9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(isopropylthiomethyl)-pyrrolidine;
- 35 (xxxii) (3S,4R)-1-[(8-aza-9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(butylthiomethyl)-pyrrolidine;

- (xxxiii) (3S,4R)-1-[(8-aza-9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(phenylthiomethyl)-pyrrolidine;
- (xxxiv) (3S,4R)-1-[(8-aza-9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(4-fluorophenylthiomethyl)-pyrrolidine;
- 5 (xxxv) (3S,4R)-1-[(8-aza-9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(4-chlorophenylthiomethyl)-pyrrolidine;
- (xxxvi) (3S,4R)-1-[(8-aza-9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(3-chlorophenylthiomethyl)-pyrrolidine;
- 10 (xxxvii) (3S,4R)-1-[(8-aza-9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(4-methylphenylthiomethyl)-pyrrolidine;
- (xxxviii) (3S,4R)-1-[(8-aza-9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(3-methylphenylthiomethyl)-pyrrolidine;
- (xxxix) (3S,4S)-1-[(8-aza-9-deazaguanin-9-yl)ethyl]-3-hydroxy-4-(hydroxymethyl)-pyrrolidine;
- 15 (xl) (3S,4S)-1-[(8-aza-9-deazaguanin-9-yl)ethyl]-3-hydroxy-4-methyl-pyrrolidine;
- (xli) (3S,4S)-1-[(8-aza-9-deazaguanin-9-yl)ethyl]-3-hydroxy-4-(methylthiomethyl)-pyrrolidine;
- (xlii) (3S,4S)-1-[(8-aza-9-deazahypoxanthin-9-yl)ethyl]-3-hydroxy-4-(hydroxymethyl)-pyrrolidine;
- 20 (xliii) (3S,4S)-1-[(8-aza-9-deazahypoxanthin-9-yl)ethyl]-3-hydroxy-4-methyl-pyrrolidine;
- (xliv) (3S,4S)-1-[(8-aza-9-deazahypoxanthin-9-yl)ethyl]-3-hydroxy-4-(methylthiomethyl)-pyrrolidine;
- (xlv) (3S,4S)-1-[(8-aza-9-deazaxanthin-9-yl)ethyl]-3-hydroxy-4-(hydroxymethyl)-pyrrolidine; and
- 25 (xlv) (3S,4S)-1-[(8-aza-9-deazaxanthin-9-yl)ethyl]-3-hydroxy-4-(hydroxymethyl)-pyrrolidine; and
- (xlv) (3S,4S)-1-[(8-aza-9-deazaxanthin-9-yl)ethyl]-3-hydroxy-4-(methylthiomethyl)-pyrrolidine.

30 In a second aspect of the invention there is provided a pharmaceutical composition comprising a pharmaceutically effective amount of a compound of formula (I).

In another aspect of the invention there is provided a method of treatment of a disease or condition in which it is desirable to inhibit purine phosphoribosyltransferase, purine nucleoside phosphorylase, 5'-methylthioadenosine phosphorylase, 5'-methylthioadenosine nucleosidase and/or nucleoside hydrolase comprising administering

35

a pharmaceutically effective amount of a compound of formula (I) to a patient requiring treatment.

5 The diseases or conditions include cancer, bacterial and protozoal infections, and T-cell mediated diseases such as psoriasis, arthritis and transplant rejection.

10 In a further aspect of the invention there is provided the use of a compound of formula (I) in the manufacture of a medicament for the treatment of one or more of these diseases or conditions.

In still a further aspect of the invention there is provided a method of preparing a compound of formula (I).

DETAILED DESCRIPTION

15 Definitions

The term "alkyl" is intended to include both straight- and branched-chain alkyl groups. The same terminology applies to the non-aromatic moiety of an aralkyl radical. Examples of alkyl groups include: methyl group, ethyl group, *n*-propyl group, *iso*-propyl group, *n*-butyl group, *iso*-butyl group, *sec*-butyl group, *t*-butyl group, *n*-pentyl group, 1,1-dimethylpropyl group, 1,2-dimethylpropyl group, 2,2-dimethylpropyl group, 1-ethylpropyl group, 2-ethylpropyl group, *n*-hexyl group and 1-methyl-2-ethylpropyl group.

25 The term "aryl" means an aromatic radical having 4 to 18 carbon atoms and includes heteroaromatic radicals. Examples include monocyclic groups, as well as fused groups such as bicyclic groups and tricyclic groups. Some examples include phenyl group, indenyl group, 1-naphthyl group, 2-naphthyl group, azulenyl group, heptalenyl group, biphenyl group, indacenyl group, acenaphthyl group, fluorenyl group, phenalenyl group, phenanthrenyl group, anthracenyl group, cyclopentacyclooctenyl group, and benzocyclooctenyl group, pyridyl group, pyrrolyl group, pyridazinyl group, pyrimidinyl group, pyrazinyl group, triazolyl group, tetrazolyl group, benzotriazolyl group, pyrazolyl group, imidazolyl group, benzimidazolyl group, indolyl group, isoindolyl group, indoliziny group, purinyl group, indazolyl group, furyl group, pyranyl group, benzofuryl group, isobenzofuryl group, thienyl group, thiazolyl group, isothiazolyl group, benzothiazolyl group, oxazolyl group, and isoxazolyl group.

35 The term "aralkyl" means an alkyl radical bearing an aryl substituent.

The term "halogen" includes fluorine, chlorine, bromine and iodine.

5 The term "optionally substituted" means, in reference to the optionally substituted group, that that group may carry one or more substituent chosen from amongst an alkyl group, an alkoxy group (wherein the alkyl group is as defined above), a halogen atom, an amino group, carboxylic acid group, an carboxylate alkyl ester group, or an alkylthio group.

10 The term "prodrug" as used herein means a pharmacologically acceptable derivative of the compound of formula (I), such that an *in vivo* biotransformation of the derivative gives the compound as defined in formula (I). Prodrugs of compounds of formula (I) may be prepared by modifying functional groups present in the compounds in such a way that the modifications are cleaved *in vivo* to give the parent compound.

15 The term "pharmaceutically acceptable salts" is intended to apply to non-toxic salts derived from inorganic or organic acids, including, for example, the following acid salts: acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptanoate, glycerophosphate, 20 glycolate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, *p*-toluenesulfonate, salicylate, succinate, sulfate, tartrate, thiocyanate, and undecanoate.

25 The term "patient" includes human and non-human animals.

Description of Inhibitor Compounds

The ethylene-linked compounds of the invention are surprisingly potent inhibitors of PNP. 30 A class of PNP inhibitor compounds containing methylene linkages is described in the applicants' PCT application PCT/NZ03/00186. The methylene-linked compounds were designed to match the fully dissociated transition states of human PNP and *Plasmodium falciparum* PNP. The applicants have carried out detailed investigations of this methylene-linked class.

Based on their particular knowledge of the PNP enzyme, and the activities of the methylene-linked compounds, the applicants would not have predicted that ethylene-linked compounds would be potent PNP inhibitors, or would even exhibit PNP inhibitory activity at all. It was previously considered that the presence of the extra carbon atom in the linkage would have rendered the ethylene class inactive. It was thought that the inclusion of an extra carbon atom in the linkage would elongate the distance between the ribose mimic (the amine moiety) and the base moiety beyond the length that had been found to be optimum for inhibition of the PNP enzyme. The prior art and the applicants' previous special knowledge of the PNP enzyme actually taught away from synthesising and investigating the activities of the ethylene-linked compounds. However, despite the linkage being outside of the predicted optimal length, the compounds of the invention prove to be surprisingly potent inhibitors of human PNP. Indeed, one compound of the invention (Compound 1) has a K_i for human PNP of 0.46 ± 0.05 nM, a potency sufficient to have therapeutic potential.

Synthesis of Inhibitor Compounds

The compounds may be prepared by any method. However, preferably they are prepared by independently synthesising the amine moiety and the base part, and then linking the base part to the nitrogen atom in the ring of the amine moiety. In one preferred embodiment, the ethylene linkage is constructed on the base part in the form of a 2-substituted acetaldehyde moiety, and then linked to the amine moiety by way of a reductive amination reaction.

General Aspects

The compounds of the invention are useful in both free base form and in the form of salts.

It will be appreciated that the representation of a compound of formula (I), where B and/or D is a hydroxy group, is of the enol-type tautomeric form of a corresponding amide, and this will largely exist in the amide form. The use of the enol-type tautomeric representation is simply to allow fewer structural formulae to represent the compounds of the invention.

The active compounds may be administered to a patient by a variety of routes, including orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally or via an implanted reservoir. The amount of compound to be administered will vary widely according to the nature of the patient and the nature and extent of the disorder to be

treated. Typically the dosage for an adult human will be in the range less than 1 to 1000 milligrams, preferably 0.1 to 100 milligrams. The specific dosage required for any particular patient will depend upon a variety of factors, including the patient's age, body weight, general health, sex, etc.

5

For oral administration the compounds can be formulated into solid or liquid preparations, for example tablets, capsules, powders, solutions, suspensions and dispersions. Such preparations are well known in the art as are other oral dosage regimes not listed here. In the tablet form the compounds may be tableted with conventional tablet bases such as lactose, sucrose and corn starch, together with a binder, a disintegration agent and a lubricant. The binder may be, for example, corn starch or gelatin, the disintegrating agent may be potato starch or alginic acid, and the lubricant may be magnesium stearate. For oral administration in the form of capsules, diluents such as lactose and dried cornstarch may be employed. Other components such as colourings, sweeteners or flavourings may be added.

15

When aqueous suspensions are required for oral use, the active ingredient may be combined with carriers such as water and ethanol, and emulsifying agents, suspending agents and/or surfactants may be used. Colourings, sweeteners or flavourings may also be added.

20

The compounds may also be administered by injection in a physiologically acceptable diluent such as water or saline. The diluent may comprise one or more other ingredients such as ethanol, propylene glycol, an oil or a pharmaceutically acceptable surfactant.

25

The compounds may also be administered topically. Carriers for topical administration of the compounds of include mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water. The compounds may be present as ingredients in lotions or creams, for topical administration to skin or mucous membranes. Such creams may contain the active compounds suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include mineral oil, sorbitan monostearate, polysorbate 60, cetyl ester wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.

30

The compounds may further be administered by means of sustained release systems. For example, they may be incorporated into a slowly dissolving tablet or capsule.

35



EXAMPLES

The following examples further illustrate the invention. It is to be appreciated that the invention is not limited to the examples.

5

Example 1: Synthesis of (3S,4S)-1-[2-(9-Deaza-hypoxanthin-9-yl)ethyl]-3-hydroxy-4-hydroxymethylpyrrolidine (1) [DAD-Et-Immucillin-H]


10



15

n-Butyllithium (5.30 mL of a 1.3 M solution in hexanes, 6.90 mmol) was added to a solution of bromide **1a** (2.00 g, 5.75 mmol) in diethyl ether (40 mL) and anisole (16 mL) under argon at -78°C . Thin-layer chromatography confirmed that no starting material remained. Dimethylformamide (4.4 mL, 57.5 mmol) was added and the mixture stirred at -78°C for 30 minutes then the mixture was allowed to warm to room temperature. Dichloromethane (200 mL) was added and the solution was washed with water (100 mL), dried and the solvent was removed. The residue was chromatographed on silica gel to give compound **1b** (1.20 g, 70%) as a white solid.

20




25


Methyltriphenylphosphonium bromide (1.20 g, 3.37 mmol) was suspended in tetrahydrofuran (25 mL) and cooled to -78°C under an atmosphere of argon. n-Butyllithium (1.94 mL of a 1.3 M solution in hexanes, 2.52 mmol) was added to give a yellow solution, which was stirred for 15 minutes. Aldehyde **1b** (0.500 g, 1.68 mmol) was added as a solid and the solution was allowed to warm to room temperature then stirred for 2 hours. The solvent was removed and the residue was chromatographed on silica gel to give compound **1c** (0.450 g, 91%) as a pale yellow solid.

30


- 13 -



- Borane dimethyl sulfide (3.12 mL, 32.9 mmol) was added to a solution of alkene **1c** (0.970 g, 3.29 mmol) in tetrahydrofuran (11 mL) under an atmosphere of argon and the solution was stirred for 18 hours at room temperature. Sodium hydroxide (1.97 g, 49.3 mmol) was dissolved in water (4 mL) then diethyl ether (2 mL) was added slowly to the solution at 0 °C. 30% Aqueous hydrogen peroxide (30% w/w, 8 mL) was added slowly and the mixture was stirred at room temperature for 3 hours. Dichloromethane (100 mL) was added and the mixture was washed with water (100 mL), dried and the solvent was removed. Chromatography of the residue on silica gel gave compound **1d** (0.670 g, 65%) as a white solid.




- Dess-Martin periodinane (176 mg, 0.415 mmol) was added to a solution of alcohol **1d** (100 mg, 0.319 mmol) in dichloromethane (2 mL) at room temperature giving a yellow precipitate. The mixture was stirred for 10 minutes then chromatographed on silica gel to give compound **1e** (41 mg, 41%). This reaction was repeated with 460 mg of alcohol **1d**, but was left for only 2 minutes with the oxidant and purification was carried out quickly. The yield of compound **1e** increased to 71%, although this material was shown to be not as pure by NMR spectroscopy.




- 14 -

Aldehyde 1e (110 mg, 0.354 mmol) was added to a solution of amine 1f (60 mg, 0.389 mmol; reference 1) in methanol (1 mL) at room temperature and the solution stirred for 15 minutes. Sodium cyanoborohydride (29 mg, 0.460 mmol) was then added to the solution, which was stirred for an additional 30 minutes. The mixture was adsorbed onto silica and chromatographed on silica gel giving compound 1g (20 mg, 14%) as a tan gum.




10% Palladium on carbon (20 mg) was added to a solution of 1g (13 mg, 0.0315 mmol) in ethanol (1 mL) and methanol saturated with ammonia (0.5 mL) and the mixture was stirred under an atmosphere of hydrogen at room temperature for 18 hours. The mixture was filtered and the solvent removed. The residue was chromatographed on silica gel to give compound 1h (5 mg, 54%) as a tan gum.



Compound 1h (4 mg, 0.137 mmol) was heated to reflux in concentrated hydrochloric acid (1 mL) for 2 hours. The solvent was removed to give compound 1 (DAD-Et-Immucillin-H) hydrochloride salt (3 mg, 73%) as a white solid.

Example 2: Synthesis of (3S,4R)-1-[2-(9-Deaza-adenin-9-yl)ethyl]-3-hydroxy-4-methylthiomethylpyrrolidine (2) [Methylthio-DAD-Et-Immucillin-A]

- 15 -



3-Cyanopropyl benzoate (2b)

A mixture of bromobutyronitrile (2a) (7.45 g, 50.3 mmol), sodium benzoate (14.5 g, 101 mmol), tetrabutylammonium hydrogen sulfate (34.2 g, 101 mmol) and molecular sieves (1 g) in dry acetone (100 ml) was heated under reflux for 4 hrs. The reaction mixture was cooled to RT and filtered through the celite pad and concentrated to dryness. Dichloromethane was added and the mixture was washed with sat. NaHCO₃ followed by water, dried and concentrated. Chromatography (EtOAc : petroleum ether, 1:4) afforded 9.5 g (100%) of (2a) as clear syrup. ¹H NMR (CDCl₃) δ 8.02-8.12 (m, 2H), 7.41-7.59 (m, 3H), 4.42 (t, 2H), 2.52 (t, 2H), 2.13 (m, 2H); ¹³C NMR δ 171.5 (C), 166.7 (C), 134.0 (CH), 133.6 (CH), 130.5 (CH), 130.1 (CH), 130.0 (CH), 128.9 (CH), 119.3 (C), 63.1 (CH₂), 25.4 (CH₂), 14.8 (CH₂).

4-(Trityloxy)butanenitrile (2c)

To a mixture of benzoate (2b) (9.5 g, 50.2 mmol) in methanol (80 ml) was added water (20 ml) and 2M NaOH (10 ml). After stirring for 1 hr at room temperature the reaction mixture was treated with 2M HCl (10 ml), stirred for 15 min and then was concentrated to dryness and dried in *vacuo* to afford a white solid which was used in the next step without further purification. The crude material in dry pyridine was treated with trityl chloride (10.49 g, 37.6 mmol), and the mixture was stirred at room temperature for 17 hrs and concentrated to dryness. Ethyl acetate was added and the mixture was washed twice with water, dried and concentrated. Chromatography (EtOAc : petroleum ether, 1:9) gave trityl derivative (2c), 15 g (91%) as a white solid. ¹H NMR (CDCl₃) δ 7.20-7.42 (m, 15H), 3.21 (t, 2H), 2.44 (t, 2H), 1.85-1.9 (m, 2H); ¹³C NMR δ 147.3 (C), 144.3 (C), 128.9 (CH), 128.3 (CH), 127.6 (CH), 127.5 (CH), 119.9 (C), 87.2 (C), 61.7 (CH₂), 26.7 (CH₂), 14.8 (CH₂).

2-((Dimethylamino)methylene)-4-(trityloxy)butanenitrile (2d)

Trityl derivative (2c) (1 g, 3.05 mmol) was dissolved in dry DMF (15 ml). Brederick's reagent (0.84 g, 4.84 mmol) was added and the reaction mixture was stirred at 130°C in a flask with a stopper for 1 hr. Brederick's reagent (0.84 g, 4.84 mmol) was added once more and the mixture was stirred at 130 °C for 2 hrs and concentrated to dryness. Chromatography (EtOAc : petroleum ether, 1:4) gave dimethylamino derivative (2d), 0.73 g (62.5 %) as a clear syrup. ¹H NMR (CDCl₃) δ 7.21-7.45 (m, 15H), 6.25 (s, 1H), 3.17 (t, 2H), 3.00 (s, 6H), 2.26 (t, 2H); ¹³C NMR δ 151.2 (CH), 144.7 (C), 129.1 (CH), 128.2 (CH), 127.3 (CH), 122.9 (C), 87.0 (C), 69.7 (C), 63.9 (CH₂), 34.5 (CH₃), 28.4 (CH₂).

(E/Z)-3-(Cyanomethylamino)-2-(trityloxymethyl)acrylonitrile (2e)

Compound (2d) (0.722 g, 1.888 mmol) was dissolved in dry methanol (50 ml). Sodium acetate (1.239 g, 15.10 mmol) and aminoacetonitrile bisulfate (1.164 g, 7.55 mmol) were added and the reaction mixture was stirred under reflux for 5 hrs. The mixture was concentrated to dryness. Chloroform was added, and the reaction mixture was then washed twice with water, dried and concentrated. Chromatography (EtOAc : petroleum ether, 1:2) gave a mixture of cis-trans isomers (2e), 0.74 g (100 %) as a pale yellow foam. ¹H NMR (CDCl₃) δ 7.22-7.44 (m, 30H), 6.61 (d, *J* = 12.0 Hz, 1H), 6.43 (d, *J* = 12.6 Hz, 1H), 5.86-5.94 (m, 1H), 4.79-4.85 (m, 1H), 3.89 (d, *J* = 6.1 Hz, 2H), 3.66 (d, *J* = 6.1 Hz, 2H), 3.35 (t, 2H), 3.18 (t, 2H), 2.26-2.32 (m, 4H); ¹³C NMR δ 146.7 (CH), 146.6 (CH), 143.0 (C), 142.2 (C), 127.6 (CH), 127.1 (CH), 126.9 (CH), 126.5 (CH), 126.1 (CH), 121.0 (C), 114.9 (C), 114.8 (C), 87.0 (C), 85.8 (C), 81.3 (C), 79.3 (C), 62.7 (CH₂), 61.5 (CH₂), 34.2 (CH₂), 33.9 (CH₂), 30.1 (CH₂), 27.7 (CH₂).

3-Amino-4-(2-(trityloxy)ethyl)-1H-pyrrole-2-carbonitrile (2f)

DBU (1.7 ml, 11.28 mmol) was added to a stirred solution of nitrile (2e) (0.74 g, 1.88 mmol) in dry dichloromethane at room temperature. Methyl chloroformate (0.44 ml, 5.64 mmol) was added drop wise and the reaction mixture was stirred at RT for 17 hrs. Methanol (4 ml) was then added and after 1 hr the resulting solution was diluted with dichloromethane (150 ml), washed with 2M HCl (20 ml), followed by aq. sodium bicarbonate (30 ml), dried (MgSO₄), and concentrated *in vacuo* to afford a syrup. Chromatography (ethyl acetate:petroleum ether, 1:2) gave pyrrole (2f), 0.508 g (68.6 %) as a clear syrup. ¹H NMR (CDCl₃) δ 7.86 (s, 1H), 7.13-7.31 (m, 15H), 6.35 (d, *J* = 3.1 Hz, 1H), 3.18 (t, 2H); 2.49 (t, 2H); ¹³C NMR δ 142.9 (C), 141.8 (C), 127.7 (CH), 126.8 (CH), 126.1 (CH), 121.3 (CH), 114.2 (C), 110.3 (C), 86.2 (C), 63.4 (CH₂), 23.9 (CH₂).

7-(2-(Trityloxy)ethyl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine (2g)

Pyrrole (2f) (0.480 g, 1.220 mmol) was dissolved in abs EtOH (15 ml). Formamidine acetate (0.635 g, 6.10 mmol) was added and the reaction mixture was heated under reflux for 4 hrs. The solution was concentrated to dryness. Chromatography (ethyl acetate) gave (2g), 0.42 g (82 %) as a solidified syrup. ¹H NMR (MeOH-d₄) δ 8.47 (s, 1H), 7.54 (s, 1H), 7.12-7.41 (m, 15H), 3.30-3.35 (m, 2H); 3.0 (t, 2H); ¹³C NMR δ 152.8 (C), 149.6 (CH), 146.0 (C), 144.6 (C), 130.2 (CH), 130.0 (CH), 129.0 (CH), 128.3 (CH), 115.3 (C), 114.0 (C), 88.2 (C), 65.1 (CH₂), 25.8 (CH₂).

***N*-Benzoyl-*N*-(7-(2-(trityloxy)ethyl)-5*H*-pyrrolo[3,2-*d*]pyrimidin-4-yl)benzamide (2h)**

Pyrrolo-pyrimidine (2f) (0.4 g, 0.951 mmol) was dissolved in dry pyridine (15 ml) and cooled to 0 °C. Benzoyl chloride (2 ml, 17.22 mmol) was added and the reaction mixture was stirred at RT for 17 hrs. The resulting solution was diluted with dichloromethane, washed with water, followed by aq. sodium bicarbonate, dried (MgSO₄), and concentrated *in vacuo* to afford a syrup. Chromatography (ethyl acetate:petroleum ether, 1:4) gave over-*N*-benzoylated material as a syrup. This was dissolved in dry MeOH (20 ml) and treated with triethylamine (1 ml). The solution was stirred at RT for 17 hrs and concentrated to dryness. Chromatography (ethyl acetate:petroleum ether, 1:2) gave (2h), 0.53 g (89%) as a white foam. ¹H NMR (CDCl₃) δ 8.4 (s, 1H), 8.1 (m, 1H), 7.8-8.0 (m, 4H), 7.13-7.49 (m, 21H), 3.4 (t, 2H); 3.1 (t, 2H); ¹³C NMR δ 171.5 (C), 167.5 (C), 151.7 (C), 148.8 (CH), 144.8 (C), 142.8 (C), 133.8 (CH), 132.2 (CH), 131.3 (CH), 130.4 (CH), 130.2 (CH), 129.1 (CH), 128.7 (CH), 128.5 (CH), 128.1 (CH), 127.3 (CH), 116.3 (C), 114.4 (C), 87.0 (C), 63.9 (CH₂), 24.9 (CH₂).

***N*-Benzoyl-*N*-(7-(2-hydroxyethyl)-5*H*-pyrrolo[3,2-*d*]pyrimidin-4-yl)benzamide (2i)**

N-Benzoyl derivative (2h) (0.2 g, 0.318 mmol) was dissolved in aq. acetic acid (80%, 5 ml) and stirred at 60 °C for 4 hrs. The resulting solution was concentrated *in vacuo* to afford a syrup. Chromatography (ethyl acetate:petroleum ether, 1:1) gave (9), 111 mg (90%) as a clear syrup.

***N*-Benzoyl-*N*-(7-(2-oxoethyl)-5*H*-pyrrolo[3,2-*d*]pyrimidin-4-yl)benzamide (2j)**

Alcohol (2i) (78 mg, 202 μmol) was dissolved in dry dichloromethane (5 ml) and treated with Dess-Martin periodinane (1.5 eq., 128 mg). The reaction mixture was stirred at RT for 1 hr. The resulting solution was diluted with ether and treated with 1M NaOH. After 15 min the organic layer was washed with water, dried (MgSO₄) and concentrated *in vacuo* to afford a syrup. Chromatography (ethyl acetate:petroleum ether, 1:1) gave (2j), 71 mg (92%) as a clear syrup.

(3*S*,4*R*)-1-[2-(9-Deaza-adenin-9-yl)ethyl]-3-hydroxy-4-methylthiomethylpyrrolidine (2) [Methylthio-DAD-Et-Immucillin-A]

Acetaldehyde-derivative (2j) can be coupled with the (3*S*,4*R*)-3-hydroxy-4-methylthiomethylpyrrolidine (2k) by reductive amination using sodium cyanoborohydride in methanol at room temperature, following methodology reported in Evans et al, *J. Med. Chem.*, 48 (2005) 4679 – 4689, (see Scheme 1), and the *N*-benzoyl protecting groups can

then be removed by treatment of the product with methanolic ammonia, to yield the title compound (2).

Example 3: Inhibition Studies

- 5 Initial (K_i) and equilibrium (K_i^*) dissociation constants of DAD-Et-Immucillin-H were determined for human PNP.

- Inhibitor dissociation constants for the phosphorolysis of inosine were based on initial and equilibrium reaction rate measurements with varied inhibitor concentrations (Miles, R. W., Tyler, P. C., Fumeaux, R. H., Bagdassarian, C. K. and Schramm, V. L. (1998) One-third-the-sites transition state inhibitors for purine nucleoside phosphorylase, *Biochemistry* 37, 8615-8621; Morrison, J. F. and Walsh, C. T. (1988) The behaviour and significance of slow-binding enzyme inhibitors, *Adv. Enzymol. Relat. Areas Mol. Biol.* 61, 201-301). Reactions were started by adding huPNP (1.4 nM) to reaction mixtures (25 °C) containing 10 1 mM inosine in 50 mM KHPO₄ pH 7.4 with xanthine oxidase at 60 mU/ml. Hypoxanthine formed by phosphorolysis of inosine was oxidized to uric acid and monitored spectrophotometrically at 293 nm (extinction coefficient for uric acid $\epsilon_{293} = 12.9 \text{ mM}^{-1} \text{ cm}^{-1}$). Enzyme concentration was adjusted to give absorbance changes not exceeding 1.0 during the time required to characterize initial and final slow-onset inhibition equilibria. 20 The large excess of substrate and continuous product depletion provided extended initial rate conditions. In most cases the concentration of the inhibitor compound was >10-fold greater than the enzyme concentration as required for simple analysis of two-state slow-onset tight-binding inhibition (Morrison, J. F. and Walsh, C. T. (1988) The behavior and significance of slow-binding enzyme inhibitors, *Adv. Enzymol. Relat. Areas Mol. Biol.* 61, 25 201-301). The inhibition constant K_i describes the reversible equilibrium between enzyme and inhibitor (compound 1) for the initial inhibitor binding step. K_i was determined by fitting the initial rates at different inhibitor concentration to the equation for competitive inhibition: $v_i = (k_{cat} \times S)/(K_m(1+I/K_i) + S)$, where v_i is initial reaction rate, k_{cat} is the catalytic turnover number, K_m is the Michaelis constant, K_i is the dissociation constant of enzyme-inhibitor complex (EI), I is inhibitor concentration and S is substrate concentration. The 30 dissociation constant for the complex formed after slow onset equilibrium (K_i^*) was determined by $v = (k_{cat} \times S)/(K_m(1+I/K_i^*) + S)$, where v is the steady state reaction rate and the other variables are the same as above.
- 35 Initial (K_i) and equilibrium (K_i^*) dissociation constants of Compound 1 for huPNP were found to be $1.6 \pm 0.3 \text{ nM}$ and $0.46 \pm 0.05 \text{ nM}$, respectively.


Although the invention has been described by way of example, it should be appreciated the variations or modifications may be made without departing from the scope of the invention. Furthermore, when known equivalents exist to specific features, such equivalents are incorporated as if specifically referred to in the specification.

INDUSTRIAL APPLICABILITY

The present invention relates to compounds that are inhibitors of PNP, PPRT, MTAP, MTAN and/or NH. The compounds are therefore expected to be useful in the treatment of diseases in which the inhibition of PNP, PPRT, MTAP, MTAN and/or NH is desirable. Such diseases include cancer, and bacterial infection, protozoal infection or T-cell mediated diseases.

CLAIMS

1. A compound of the formula (I):



where:

- 5 A is N or CH;
 B is OH or NH₂;
 D is H, OH, NH₂ or SCH₃; and
 Z is OH or SQ, where Q is an optionally substituted alkyl, aralkyl, or aryl group;
- 10 or a tautomer thereof; or a pharmaceutically acceptable salt thereof; or an ester prodrug form thereof.
2. A compound as claimed in claim 1 where A is CH.
- 15 3. A compound as claimed in claim 1 where A is N.
4. A compound as claimed in any one of claims 1 to 3 where B is OH.
5. A compound as claimed in any one of claims 1 to 3 where B is NH₂.
- 20 6. A compound as claimed in any one of claims 1 to 5 where D is H.
7. A compound as claimed in claim 1 where A is CH and D is H.
- 25 8. A compound as claimed in any one of claims 1 to 6 where D is NH₂, OH, or SCH₃.
9. A compound as claimed in any one of the preceding claims where Z is OH.
- 30 10. A compound as claimed in any one of claims 1 to 8 where Z is SQ.

11. A compound as claimed in claim 1 where Z is OH, A is CH, B is OH, and D is H or NH₂.
- 5 12. A compound as claimed in claim 1 where Z is SQ, A is CH, B is NH₂, and D is H.
13. A compound as claimed in claim 1 which is selected from the group:
- 10 (xlvii) (3S,4S)-1-[(9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(hydroxymethyl)-pyrrolidine;
- (xlviii) (3S,4R)-1-[(9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(methylthiomethyl)-pyrrolidine;
- (xlix) (3S,4R)-1-[(9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(ethylthiomethyl)-pyrrolidine;
- 15 (i) (3S,4R)-1-[(9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(2-fluoroethylthiomethyl)-pyrrolidine;
- (ii) (3S,4R)-1-[(9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(2-hydroxyethylthiomethyl)-pyrrolidine;
- 20 (iii) (3S,4R)-1-[(9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(propylthiomethyl)-pyrrolidine;
- (liii) (3S,4R)-1-[(9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(isopropylthiomethyl)-pyrrolidine;
- (liv) (3S,4R)-1-[(9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(butylthiomethyl)-pyrrolidine;
- 25 (iv) (3S,4R)-1-[(9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(cyclohexylthiomethyl)-pyrrolidine;
- (lvi) (3S,4R)-1-[(9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(cyclohexylmethylthiomethyl)-pyrrolidine;
- (lvii) (3S,4R)-1-[(9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(cyclopentylthiomethyl)-pyrrolidine;
- 30 (lviii) (3S,4R)-1-[(9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(phenylthiomethyl)-pyrrolidine;

- (lix) (3S,4R)-1-[(9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(4-fluorophenylthiomethyl)-pyrrolidine;
- (lx) (3S,4R)-1-[(9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(4-chlorophenylthiomethyl)-pyrrolidine;
- 5 (lxi) (3S,4R)-1-[(9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(3-chlorophenylthiomethyl)-pyrrolidine;
- (lxii) (3S,4R)-1-[(9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(4-methylphenylthiomethyl)-pyrrolidine;
- (lxiii) (3S,4R)-1-[(9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(3-methylphenylthiomethyl)-pyrrolidine;
- 10 (lxiv) (3S,4R)-1-[(9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(benzylthiomethyl)-pyrrolidine;
- (lxv) (3S,4S)-1-[(9-deazaguanin-9-yl)ethyl]-3-hydroxy-4-(hydroxymethyl)-pyrrolidine;
- 15 (lxvi) (3S,4R)-1-[(9-deazaguanin-9-yl)ethyl]-3-hydroxy-4-(methylthiomethyl)-pyrrolidine;
- (lxvii) (3S,4S)-1-[(9-deazahypoxanthin-9-yl)ethyl]-3-hydroxy-4-(hydroxymethyl)-pyrrolidine;
- (lxviii) (3S,4R)-1-[(9-deazahypoxanthin-9-yl)ethyl]-3-hydroxy-4-(methylthiomethyl)-pyrrolidine;
- 20 (lix) (3S,4S)-1-[(9-deazaxanthin-9-yl)ethyl]-3-hydroxy-4-(hydroxymethyl)-pyrrolidine;
- (lxx) (3S,4S)-1-[(9-deazaxanthin-9-yl)ethyl]-3-hydroxy-4-(methylthiomethyl)-pyrrolidine;
- 25 (lxxi) (3S,4S)-1-[(8-aza-9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(hydroxymethyl)-pyrrolidine;
- (lxxii) (3S,4S)-1-[(8-aza-9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-methyl-pyrrolidine;
- (lxxiii) (3S,4R)-1-[(8-aza-9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(benzylthiomethyl)-pyrrolidine;
- 30 (lxxiv) (3S,4R)-1-[(8-aza-9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(methylthiomethyl)-pyrrolidine;
- (lxxv) (3S,4R)-1-[(8-aza-9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(ethylthiomethyl)-pyrrolidine;
- 35 (lxxvi) (3S,4R)-1-[(8-aza-9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(propylthiomethyl)-pyrrolidine;

- (lxxvii) (3S,4R)-1-[(8-aza-9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(isopropylthiomethyl)-pyrrolidine;
- (lxxviii) (3S,4R)-1-[(8-aza-9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(butylthiomethyl)-pyrrolidine;
- 5 (lxxix) (3S,4R)-1-[(8-aza-9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(phenylthiomethyl)-pyrrolidine;
- (lxxx) (3S,4R)-1-[(8-aza-9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(4-fluorophenylthiomethyl)-pyrrolidine;
- (lxxxi) (3S,4R)-1-[(8-aza-9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(4-chlorophenylthiomethyl)-pyrrolidine;
- 10 (lxxxii) (3S,4R)-1-[(8-aza-9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(3-chlorophenylthiomethyl)-pyrrolidine;
- (lxxxiii) (3S,4R)-1-[(8-aza-9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(4-methylphenylthiomethyl)-pyrrolidine;
- 15 (lxxxiv) (3S,4R)-1-[(8-aza-9-deazaadenin-9-yl)ethyl]-3-hydroxy-4-(3-methylphenylthiomethyl)-pyrrolidine;
- (lxxxv) (3S,4S)-1-[(8-aza-9-deazaguanin-9-yl)ethyl]-3-hydroxy-4-(hydroxymethyl)-pyrrolidine;
- (lxxxvi) (3S,4S)-1-[(8-aza-9-deazaguanin-9-yl)ethyl]-3-hydroxy-4-methyl-pyrrolidine;
- 20 (lxxxvii) (3S,4S)-1-[(8-aza-9-deazaguanin-9-yl)ethyl]-3-hydroxy-4-(methylthiomethyl)-pyrrolidine;
- (lxxxviii) (3S,4S)-1-[(8-aza-9-deazahypoxanthin-9-yl)ethyl]-3-hydroxy-4-(hydroxymethyl)-pyrrolidine;
- (lxxxix) (3S,4S)-1-[(8-aza-9-deazahypoxanthin-9-yl)ethyl]-3-hydroxy-4-methyl-pyrrolidine;
- 25 (xc) (3S,4S)-1-[(8-aza-9-deazahypoxanthin-9-yl)ethyl]-3-hydroxy-4-(methylthiomethyl)-pyrrolidine;
- (xci) (3S,4S)-1-[(8-aza-9-deazaxanthin-9-yl)ethyl]-3-hydroxy-4-(hydroxymethyl)-pyrrolidine; and
- 30 (xcii) (3S,4S)-1-[(8-aza-9-deazaxanthin-9-yl)ethyl]-3-hydroxy-4-(methylthiomethyl)-pyrrolidine.

14. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound of claim 1.

15. A pharmaceutical composition as claimed in claim 14 where the compound of claim 1 is one where Z is OH, A is CH, B is OH, and D is H or NH₂.
- 5 16. A pharmaceutical composition as claimed in claim 14 where the compound of claim 1 is one where Z is SQ, A is CH, B is NH₂, and D is H.
- 10 17. A method of treatment of a disease or condition in which it is desirable to inhibit purine phosphoribosyltransferase, purine nucleoside phosphorylase, 5'-methylthioadenosine phosphorylase nucleoside, 5'-methylthioadenosine dase and/or nucleoside hydrolase comprising administering a pharmaceutically effective amount of a compound as claimed in any one of claims 1 to 13 to a patient requiring treatment.
- 15 18. A method as claimed in claim 17 where the disease or condition is cancer, bacterial infection, protozoal infection or a T-cell mediated disease.
19. A method as claimed in claim 18 where the T-cell mediated disease is psoriasis, arthritis or transplant rejection.
- 20 20. A method as claimed in any one of claims 17 to 19 where the compound of claim 1 is one where Z is OH, A is CH, B is OH, and D is H or NH₂.
21. A method as claimed in any one of claims 17 to 19 where the compound of claim 1 is one where Z is SQ, A is CH, B is NH₂, and D is H.
- 25 22. The use of a compound as claimed in any one of claims 1 to 13 in the manufacture of a medicament for treating a disease or condition in which it is desirable to inhibit purine phosphoribosyltransferase, purine nucleoside phosphorylase, 5'-methylthioadenosine phosphorylase, 5'-methylthioadenosine nucleosidase and/or nucleoside hydrolase.
- 30 23. The use as claimed in claim 22 where the disease or condition is cancer, bacterial infection, protozoal infection or a T-cell mediated disease.
- 35 24. The use as claimed in claim 23 where the T-cell mediated disease is psoriasis, arthritis or transplant rejection.

25. The use as claimed in any one of claims 22 to 24 where the compound of claim 1 is one where Z is OH, A is CH, B is OH, and D is H or NH₂.
- 5 26. The use as claimed in any one of claims 22 to 24 where the compound of claim 1 is one where Z is SQ, A is CH, B is NH₂, and D is H.
- 10 27. A method of preparing a compound according to claim 1 where a 2-(9-deaza-puine-9-yl)acetaldehyde, or protected form thereof, is coupled by reductive amination to (3R,4S)-3-hydroxy-4-hydroxymethylpyrrolidine.
- 15 28. A method of preparing a compound according to claim 1 where a 2-(9-deaza-puine-9-yl)acetaldehyde, or protected form thereof, is coupled by reductive amination to a (3R,4S)-3-hydroxy-4-alkyl-, 4-aralkyl- or aryl-thiomethylpyrrolidine, where the alkyl-, aralkyl- or aryl groups are each optionally substituted.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/NZ2006/000123

A. CLASSIFICATION OF SUBJECT MATTER

Int. Cl.

C07D 473/00 (2006.01) A61P 31/00 (2006.01) C07D 473/30 (2006.01)
 A61K 31/52 (2006.01) C07D 473/04 (2006.01) C07D 473/34 (2006.01)
 A61K 31/522 (2006.01) C07D 473/18 (2006.01)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
 File Registry substructure search based on Formula (I)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	Lewandowicz A. et al., "Energetic Mapping of Transition State Analogue Interactions with Human and <i>Plasmodium falciparum</i> Purine Nucleotide Phosphorylases" Journal of Biological Chemistry (2005), 280(34), 30320-30328. See compound DADEt-ImmH on page 30325.	1, 2, 4, 6, 7, 9, 11, 13
A	WO 2004/018496 A1 (ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY) 4 March 2004 See Schemes 3, 5, 13, and 16.	27-28
A	WO 2000/061783 A2 (INDUSTRIAL RESEARCH LIMITED) 19 October 2000 See whole document	1-28


☒ Further documents are listed in the continuation of Box C ☒ See patent family annex

- * Special categories of cited documents:
- "A" document defining the general state of the art which is not considered to be of particular relevance
 - "E" earlier application or patent but published on or after the international filing date
 - "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 - "O" document referring to an oral disclosure, use, exhibition or other means
 - "P" document published prior to the international filing date but later than the priority date claimed
 - "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
 - "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
 - "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
 - "&" document member of the same patent family

Date of the actual completion of the international search
 07 August 2006

Date of mailing of the international search report
 24 AUG 2006

Name and mailing address of the ISA/AU
 AUSTRALIAN PATENT OFFICE
 PO BOX 200, WODEN ACT 2606, AUSTRALIA
 E-mail address: pct@ipaustalia.gov.au
 Facsimile No. (02) 6285 3929

Authorized officer

 IAN DOWD
 Telephone No : (02) 6283 2273

INTERNATIONAL SEARCH REPORT

International application No.

PCT/NZ2006/000123

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2002/018371 A1 (INDUSTRIAL RESEARCH LIMITED) 7 March 2002 See whole document	1-28
A	WO 2003/080620 A1 (INDUSTRIAL RESEARCH LIMITED) 2 October 2003 See whole document	1-28

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/NZ2006/000123

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report				Patent Family Member			
WO	2004018496	AU	2003258911	BR	0313664	CA	2496698
		CN	1692120	EP	1539783	RU	2005107714
WO	0061783	AU	38469/00	CA	2368095	CN	1370171
		CN	1727341	EP	1165564	NZ	514660
		US	6693193	US	7022852	US	2004181063
		US	2006089498				
WO	0218371	AU	84564/01	US	2004053944		
WO	03080620	AU	2003215969	CA	2480470	EP	1490373
		US	2004110772				
Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.							
END OF ANNEX							